The UK Competition Authority accepts legally binding commitments from a pharmaceutical company in order to secure the affordable supply of a key drug (Essential Pharma)

CMA secures affordable supply of key bipolar drug* The CMA has accepted legally binding commitments from Essential Pharma to continue supplying a key bipolar drug at an affordable price for at least 5 years. In October, the CMA launched an investigation suspecting that the pharmaceutical supplier, Essential Pharma, may have abused a dominant market position by adopting a strategy to withdraw the bipolar drug, Priadel, from UK patients. This would have caused disruption for patients and

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

  • United Kingdom’s Competition Authority - CMA (London)

Citation

UK Competition Authority, The UK Competition Authority accepts legally binding commitments from a pharmaceutical company in order to secure the affordable supply of a key drug (Essential Pharma), 18 décembre 2020, e-Competitions December 2020, Art. N° 98528

Visites 262

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues